Lyell Immunopharma, Inc.
LYEL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $61 | $130 | $84,683 | $10,650 |
| % Growth | -53.1% | -99.8% | 695.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $61 | $130 | $84,683 | $10,650 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $171,603 | $182,945 | $159,188 | $138,693 |
| G&A Expenses | $52,041 | $66,983 | $117,307 | $89,057 |
| SG&A Expenses | $52,041 | $66,983 | $117,307 | $89,057 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $135,172 | -$2,790 | -$4,754 | -$2,324 |
| Operating Expenses | $358,816 | $247,138 | $271,741 | $225,426 |
| Operating Income | -$358,755 | -$247,008 | -$187,058 | -$214,776 |
| % Margin | -588,123% | -190,006.2% | -220.9% | -2,016.7% |
| Other Income/Exp. Net | $15,761 | $12,376 | $3,940 | -$35,443 |
| Pre-Tax Income | -$342,994 | -$234,632 | -$183,118 | -$250,219 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$342,994 | -$234,632 | -$183,118 | -$250,219 |
| % Margin | -562,285.2% | -180,486.2% | -216.2% | -2,349.5% |
| EPS | -1.31 | -0.935 | -0.741 | -1.031 |
| % Growth | -40.1% | -26.1% | 28.1% | – |
| EPS Diluted | -1.31 | -0.935 | -0.741 | -1.031 |
| Weighted Avg Shares Out | 13,074 | 12,549 | 12,354 | 12,137 |
| Weighted Avg Shares Out Dil | 13,074 | 12,549 | 12,354 | 12,137 |
| Supplemental Information | – | – | – | – |
| Interest Income | $24,068 | $23,453 | $7,053 | $1,165 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $19,631 | $20,250 | $18,020 | $13,624 |
| EBITDA | -$200,643 | -$226,758 | -$169,038 | -$201,152 |
| % Margin | -328,923% | -174,429.2% | -199.6% | -1,888.8% |